Drug intelligence / Profile preview

BI 1356 + ritonavir

Development stage: Preclinical
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

BI 1356 + ritonavir is a combination of linagliptin (BI 1356) and ritonavir. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, primarily developed for the treatment of type 2 diabetes mellitus. Ritonavir is a protease inhibitor commonly used as a pharmacokinetic enhancer due to its potent inhibition of cytochrome P450 3A4 (CYP3A4), which increases the plasma concentration of co-administered drugs. In this combination, ritonavir is utilized to inhibit the metabolism of linagliptin, potentially allowing for higher drug exposure or less frequent dosing of linagliptin. This combination is experimental and is not approved or marketed as a fixed-dose product.

Other names: linagliptin + ritonavir

Targets

CYP3A4 (Cytochrome P450 3A4)DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on BI 1356 + ritonavir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 1356 + ritonavir.

Explore the full profile